市場調査レポート

幹細胞治療市場

Stem Cell Therapeutics Markets (Cardiovascular and Circulatory Diseases, Endocrine Diseases, Digestive Disorders, Musculoskeletal, Nervous System, Cancer and Others)

発行 Kalorama Information 商品コード 317415
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
幹細胞治療市場 Stem Cell Therapeutics Markets (Cardiovascular and Circulatory Diseases, Endocrine Diseases, Digestive Disorders, Musculoskeletal, Nervous System, Cancer and Others)
出版日: 2014年10月09日 ページ情報: 英文 214 Pages
概要

幹細胞は、様々な疾患や外傷により欠損あるいは損傷した細胞に置き換えることができる可能性があり、新たな再生療法に発展しうることから、非常に大きな関心を寄せられています。血液疾患、筋骨格疾患、消化器疾患、およびその他多くの分野において、幹細胞は効果的なツールとなってきています。

当レポートでは、幹細胞治療市場を取り上げ、現在の技術の性能を評価し、新たな技術の開発状況、価格動向、幹細胞に関する政府の取り組みなど、幹細胞市場における機会を分析し、幹細胞市場の予測をまとめるなど、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

  • 概要と調査範囲
  • 調査手法
  • 用語集
  • 市場規模と市場の成長

第2章 幹細胞:イントロダクション

  • 概要
  • 幹細胞の種類
  • 成体幹細胞
  • ヒトES(胚性幹)細胞
  • 幹細胞の採取
  • 成体幹細胞の採取
  • 末梢血アフェレーシス
  • 骨髄幹細胞
  • 臍帯血幹細胞
  • ES(胚性幹)細胞の採取
  • 幹細胞の移植
  • 幹細胞移植の取り組み
  • 自家移植
  • 同種移植
  • 移植片対宿主疾患
  • 薬物研究用途

第3章 規制情勢と調査方針

  • 幹細胞規制の概要
  • 幹細胞研究の倫理面
  • 米国の規制
  • 早期対応、画期的療法、迅速承認および先行調査
  • 米国:ES細胞に関する州および連邦イニシアチブ
  • カナダ:幹細胞研究指針
  • 欧州連合:ヒトESに対する加盟国の規制上の立場
  • 英国:ES細胞に関するイニシアチブ
  • ポルトガル:ES細胞研究における変化
  • アジア:幹細胞研究に関して活力ある市場
  • 中国:幹細胞研究方針
  • シンガポール:新興市場
  • 韓国:活気ある幹細胞市場
  • 国別幹細胞開発業者

第4章 開発のプロファイルおよび分析

  • 概要
  • 胚性研究と開発の取り組み
  • 幹細胞技術特許
  • 開発プログラム
  • 開発業者市場業績

第5章 治療用途:現在および潜在的な幹細胞部門

  • 概要
  • 疾患の統計
  • 血液および造血臓器の疾患
  • 循環器系疾患
  • 内分泌・新陳代謝システムの疾患および免疫疾患
  • 眼疾患
  • 消化器系疾患
  • 筋骨格系疾患および結合組織疾患
  • 腫瘍
  • 神経系疾患
  • 呼吸器系疾患
  • 皮膚および皮下組織の疾患

第6章 幹細胞市場のサマリーと展望

  • 概要
  • 幹細胞の予測分析
    • 疾患分類別幹細胞予測分析
  • 総括

付録:参入企業

図表リスト

目次
Product Code: KLI5348147

There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.

Kalorama Information's Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts.

Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments:

  • Blood and Blood-Forming Organs
  • Circulatory System
  • Endocrine and Metabolic System and Immunity Disorders
  • Eye
  • Gastrointestinal System
  • Musculoskeletal System and Connective Tissue Disorders
  • Neoplasms
  • Nervous System
  • Respiratory System
  • Skin and Subcutaneous Tissues

There are more than 4,000 research projects underway for stem cell therapies throughout the world. About a dozen companies worldwide are currently evaluating stem cell therapies in late stage clinical trials. Companies discussed in this report include those which have registered trials in Phase I through Phase III development. These include:

  • Aastrom Biosciences
  • Advanced Cell Technology
  • Anterogen
  • Antria
  • apceth
  • Arteriocyte
  • Athersys
  • Baxter
  • BioCardia
  • Bioheart
  • BrainStorm Cell
  • Capricor
  • Celgene
  • Cytomedix
  • Cytori
  • Gamida Cell
  • GlaxoSmithKline
  • ISCO
  • Intrexon
  • ISTO
  • Medipost
  • Mesoblast
  • NeoStem
  • Neuralstem
  • Pharmicell
  • Pluristem
  • ReNeuron
  • SanBio
  • StemCells
  • Stemedica Cell
  • Stempeutics
  • Targazyme
  • TiGenix
  • ViaCyte

Information for this report was gathered using both primary and secondary research. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians; secondary sources include comprehensive research of company reports and literature, government documents and databases, research journals and reports and general medical and business journals. Forecast dollar figures represent the estimated global market and are expressed in current dollars. Forecasts are provided through 2025. The size of each market segment refers to manufacturers' revenues.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Overview and Scope of Study
  • Methodology
  • Glossary of Terms
  • Size and Growth of the Market

TWO: STEM CELLS: AN INTRODUCTION

  • Overview
  • Types of Stem Cells
  • Adult Stem Cells
  • Human Embryonic Stem Cells
  • Stem Cell Harvesting
  • Harvesting Adult Stem Cells
  • Peripheral Blood Apheresis
  • Bone Marrow Stem Cells
  • Cord Blood Stem Cells
  • Harvesting Embryonic Stem Cells
  • Transplantation of Stem Cells
  • Stem Cell Transplant Approaches
  • Autologous Transplantation
  • Allogeneic Transplantation
  • Graft-versus-host Disease
  • Drug Research Applications

THREE: REGULATORY LANDSCAPE AND RESEARCH POLICY

  • Overview of Stem Cell Regulation
  • The Ethical Side of Stem Cell Research
  • U.S. Regulation
  • Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review
  • Fast Track
  • Breakthrough Therapy
  • Accelerated Approval
  • Priority Review
  • United States: State and Federal Initiatives on Embryonic Stem Cells
  • Research Funding
  • State 'Right to Try' Laws
  • For-Profit Stem Cell Clinics
  • Regulatory Actions
  • Canada: Stem Cell Research Guidelines
  • European Union: Member States' Regulatory Position on Human Embryonic Stem
  • Cell Research
  • United Kingdom: Initiatives on Embryonic Stem Cells
  • Portugal: Changes in Embryonic Stem Cell Research
  • Asia: A Vibrant Market for Stem Cell Research
  • China: Stem Cell Research Policies
  • Singapore: An Emerging Market
  • South Korea: An Active Stem Cell Market
  • Stem Cell Developers by Country of Operation

FOUR: DEVELOPMENT PROFILES AND ANALYSIS

  • Overview
  • The Embryonic Research and Development Approach
  • Stem Cell Technology Patents
  • Development Programs
  • Aastrom Biosciences, Inc.
  • Advanced Cell Technology
  • AlloCure, Inc.
  • Anterogen Co., Ltd.
  • Antria, Inc.
  • apceth GmbH & Co. KG
  • Arteriocyte, Inc.
  • Athersys, Inc.
  • Baxter International
  • BioCardia, Inc.
  • Bioheart, Inc.
  • BrainStorm Cell Therapeutics, Inc.
  • Capricor Therapeutics, Inc.
  • Celgene Cellular Therapeutics
  • Cytomedix, Inc.
  • Cytori Therapeutics, Inc.
  • Gamida Cell Ltd.
  • GlaxoSmithKline plc
  • Histogenics Corporation
  • International Stem Cell Corporation
  • ISTO Technologies, Inc.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • NeoStem, Inc.
  • Neuralstem, Inc.
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics, Inc.
  • ReNeuron Group plc
  • SanBio, Inc.
  • StemCells, Inc.
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Targazyme, Inc.
  • TiGenix NV
  • ViaCyte, Inc.
  • Developer Market Performance: Projected 2025

FIVE: THERAPEUTIC APPLICATIONS: CURRENT AND POTENTIAL STEM CELL SEGMENTS

  • Overview
  • Disease Stats
  • Diseases of the Blood and Blood-Forming Organs
  • Aplastic Anemia
  • Sickle-Cell Disease
  • Diseases of the Circulatory System
  • Cardiovascular Disease
  • Atherosclerosis
  • Congestive Heart Failure
  • Critical Limb Ischemia
  • Myocardial Infarction
  • Diseases of the Endocrine and Metabolic System and Immunity Disorders
  • Diabetes
  • Graft-versus-host Disease
  • Primary Immune Deficiency
  • Systemic Lupus Erythematosus
  • Diseases of the Eye
  • Macular Degeneration
  • Diabetic Retinopathy
  • Blindness
  • Diseases of the Gastrointestinal System
  • Intestinal Diseases
  • Crohn's Disorders
  • Liver Failure
  • Liver Transplantation
  • Diseases of the Musculoskeletal System and Connective Tissue Disorders
  • Arthritis
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Orthopedic Surgery
  • Osteoporosis
  • Neoplasms
  • Bladder Cancer
  • Brain Cancer
  • Glioblastoma
  • Neuroblastoma
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Esophageal Cancer
  • Kidney
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Diseases of the Nervous System
  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Parkinson's Disease
  • Diseases of the Respiratory System
  • Asthma
  • COPD
  • Diseases of the Skin and Subcutaneous Tissues
  • Chronic Skin Wounds
  • Burn Skin Wounds

SIX: STEM CELL MARKET SUMMARY AND OUTLOOK

  • Overview
  • Stem Cell Forecast Analysis
  • Stem Cell Market Analysis by Disease Classification
  • Disease Summary
  • Stem Cell Outlook in Circulatory / Cardiovascular Diseases
  • Stem Cell Outlook in Atherosclerosis
  • Stem Cell Outlook in Heart Failure
  • Stem Cell Outlook in Critical Limb Ischemia
  • Stem Cell Outlook in Myocardial Infarction
  • Stem Cell Outlook in Metabolic / Endocrine Diseases and Immunology Disorders . 178
  • Stem Cell Market Outlook: Diabetes
  • Stem Cell Outlook in Graft-versus-host Disease
  • Stem Cell Outlook in Systemic Lupus Erythematosus
  • Stem Cell Outlook in Digestive Disorders
  • Stem Cell Outlook in Crohn's Disease
  • Stem Cell Outlook in Liver Failure
  • Stem Cell Outlook in Musculoskeletal Diseases
  • Stem Cell Outlook in Osteoarthritis
  • Stem Cell Outlook in Osteoporosis
  • Stem Cell Outlook in Orthopedic Trauma
  • Stem Cell Outlook in Rheumatoid Arthritis
  • Stem Cell Outlook in Cancer
  • Stem Cell Outlook by Cancer Type
  • Bladder Cancer Focus
  • Esophageal Cancer Focus
  • Leukemia Focus
  • Lymphoma Focus
  • Melanoma Focus
  • Multiple Myeloma Focus
  • Stem Cell Outlook in Nervous System Disorders
  • Stem Cell Outlook in Alzheimer's Disease
  • Stem Cell Outlook in Amyotrophic Lateral Sclerosis
  • Stem Cell Outlook in Multiple Sclerosis
  • Stem Cell Outlook in Parkinson's Disease
  • Stem Cell Outlook in Skin Disorders
  • Stem Cell Outlook in Wound Healing
  • Stem Cell Outlook in Wrinkles and Aging Skin Conditions
  • Stem Cells in Other Areas of Focus
  • Asthma Outlook
  • Chronic Obstructive Pulmonary Disease Outlook
  • Incontinence Outlook
  • Macular Degeneration Outlook
  • Male Infertility Outlook
  • Tooth Regeneration Outlook
  • Conclusion

APPENDIX: INDUSTRY PARTICIPANTS

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Figure 1-1
  • Stem Cell Therapeutics Market Value, 2010 to 2025

TWO: STEM CELLS: AN INTRODUCTION

  • Table 2-1: Compare and Contrast: Adult vs. Embryonic Stem Cells

THREE: REGULATORY LANDSCAPE AND RESEARCH POLICY

  • Table 3-1: NIH Funding Trends for Stem Cell Research, Actual FY 2002 - 2013 and Estimated FY 2014 - 2015
  • Table 3-2: European Union Member State Positions on Human Embryonic Stem Cell Research
  • Figure 3-1: Distribution of Stem Cell Developers by Registered Country

FOUR: DEVELOPMENT PROFILES AND ANALYSIS

  • Figure 4-1: Distribution of Stem Cell Development Projects by Broad Indication
  • Figure 4-2: Number of Stem Cell Development Projects by Developer
  • Table 4-1: Phase III Developments in Stem Cell Therapies, Selected Projects
  • Table 4-2: Phase II Developments in Stem Cell Therapies, Selected Projects
  • Table 4-3: Phase I Developments in Stem Cell Therapies, Selected Projects
  • Table 4-4: Preclinical Developments in Stem Cell Therapies, Selected Projects
  • Figure 4-3: Aastrom Biosciences Stem Cell Pipeline Overview
  • Figure 4-4: Advanced Cell Technology Stem Cell Pipeline Overview
  • Figure 4-5: AlloCure Stem Cell Pipeline Overview
  • Figure 4-6: Anterogen Stem Cell Pipeline Overview
  • Figure 4-7: Antria Stem Cell Pipeline Overview
  • Figure 4-8: apceth Stem Cell Pipeline Overview
  • Figure 4-9: Arteriocyte Stem Cell Pipeline Overview
  • Figure 4-10: Athersys Stem Cell Pipeline Overview
  • Figure 4-11: Baxter International Stem Cell Pipeline Overview
  • Figure 4-12: BioCardia Stem Cell Pipeline Overview
  • Figure 4-13: Bioheart Stem Cell Pipeline Overview
  • Figure 4-14: BrainStorm Cell Therapeutics Stem Cell Pipeline Overview
  • Figure 4-15: Capricor Therapeutics Stem Cell Pipeline Overview
  • Figure 4-16: Celgene Cellular Therapeutics Stem Cell Pipeline Overview
  • Figure 4-17: Cytomedix Stem Cell Pipeline Overview
  • Figure 4-18: Cytori Therapeutics Stem Cell Pipeline Overview
  • Figure 4-19: Gamida Cell Stem Cell Pipeline Overview
  • Figure 4-20: GlaxoSmithKline Stem Cell Pipeline Overview
  • Figure 4-21: Histogenics Stem Cell Pipeline Overview
  • Figure 4-22: International Stem Cell Corporation Stem Cell Pipeline Overview
  • Figure 4-23: ISTO Technologies Stem Cell Pipeline Overview
  • Figure 4-24: Medipost Stem Cell Pipeline Overview
  • Figure 4-25: Mesoblast Stem Cell Pipeline Overview
  • Figure 4-26: NeoStem Stem Cell Pipeline Overview
  • Figure 4-27: Neuralstem Stem Cell Pipeline Overview
  • Figure 4-28: Pharmicell Stem Cell Pipeline Overview
  • Figure 4-29: Pluristem Therapeutics Stem Cell Pipeline Overview
  • Figure 4-30: ReNeuron Stem Cell Pipeline Overview
  • Figure 4-31: SanBio Stem Cell Pipeline Overview
  • Figure 4-32: StemCells Stem Cell Pipeline Overview
  • Figure 4-33: Stemedica Cell Technologies Stem Cell Pipeline Overview
  • Figure 4-34: Stempeutics Research Stem Cell Pipeline Overview
  • Figure 4-35: Targazyme Stem Cell Pipeline Overview
  • Figure 4-36: TiGenix Stem Cell Pipeline Overview
  • Figure 4-37: ViaCyte Stem Cell Pipeline Overview
  • Figure 4-38: Stem Cell Therapeutics: Sales by Select Developer, Projected 2025

FIVE: THERAPEUTIC APPLICATIONS: CURRENT AND POTENTIAL STEM CELL SEGMENTS

  • Table 5-1: Global Prevalence of Selected Medical Conditions with Potential Stem Cell Therapy Benefits
  • Table 5-2: Leukemia Overview by Type
  • Figure 5-1: Distribution of Leukemia Cases by Type
  • Table 5-3: Types of Primary Lung Cancer
  • Table 5-4: Classification of Non-Hodgkin's Lymphomas
  • Table 5-5: Malignant Conditions of the Skin

SIX: STEM CELL MARKET SUMMARY AND OUTLOOK

  • Figure 6-1: Stem Cell Therapeutics Market Value, 2010 to 2025
  • Figure 6-2: Stem Cell Therapeutics Market by Disease Classification, 2010 - 2025 (Skin & Subcutaneous Tissue, Nervous System, Neoplasms, Musculoskeletal System and Connective Tissue, Digestive System, Endocrine / Metabolic / Immunology, Circulatory System, Other Systems)
  • Figure 6-3: Stem Cell Therapeutics Market Distribution by Disease Classification, 2025
  • Table 6-1: Population Affected by Select Diseases and Conditions by Type
  • Figure 6-4: Global Prevalence of Selected Medical Conditions, Over 100 Million Affected, with Potential Stem Cell Therapy Benefits
  • Figure 6-5: Circulatory / Cardiovascular Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Figure 6-6: Endocrine / Metabolic and Immunology Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Table 6-2: World Diabetes Prevalence by Country
  • Figure 6-7: World Diabetes Prevalence by Country
  • Figure 6-8: Digestive Disorder Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Figure 6-9: Musculoskeletal Disease Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Figure 6-10: Estimated World Prevalence of Rheumatoid Arthritis by Select Region
  • Figure 6-11: Cancer Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Table 6-3: World Cancer Incidence by Selected Types of Cancer, 2012 and 2025, All Races, All Ages, Both Genders
  • Figure 6-12: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2012 and 2025
  • Figure 6-13: Nervous System Disorder Stem Cell Therapeutics Market Outlook, 2010 - 2025
  • Figure 6-14: Estimated World Prevalence and Incidence of Alzheimer's Diseases by Region
  • Table 6-4: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
  • Figure 6-15: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
  • Figure 6-16: Skin Disorder Stem Cell Therapeutics Market Outlook, 2010 - 2025
Back to Top